Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael H Schwenk

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Kidney360|January 18, 2024
Carboplatin Dosing on the Basis of Renal Function: 30+ Years after CalvertMichael H Schwenk
Pharmacotherapy|December 25, 2009
Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney diseaseMichael H Schwenk
The New England Journal of Medicine|July 9, 2003
Eplerenone in patients with left ventricular dysfunctionDaniel A Blaustein, Michael H Schwenk
Advances in Chronic Kidney Disease|March 17, 2016
Drug Transporter Function--Implications in CKDMichael H Schwenk, Amy Barton Pai
Kidney International|June 1, 2012
Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?Jonathan Hogan, Michael H Schwenk, Jai Radhakrishnan
Advances in Chronic Kidney Disease|February 24, 2015
Aldosterone blockade in CKD: emphasis on pharmacologyMichael H Schwenk, Jamie S Hirsch, Andrew S Bomback
Nephron. Clinical Practice|February 28, 2004
Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron productsChaim Charytan, Michael H Schwenk, Mourhege M Al-Saloum, et al.
The American Journal of Cardiology|September 17, 2002
Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockadeDaniel A Blaustein, Krishnan Babu, Arpitha Reddy, et al.
Artificial Organs|June 5, 2003
Prediction of single-pool Kt/v based on clinical and hemodialysis variables using multilinear regression, tree-based modeling, and artificial neural networksAlexander Goldfarb-Rumyantzev, Michael H Schwenk, Samuel Liu, et al.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)|September 26, 2002
New empiric expressions to calculate single pool Kt/V and equilibriated Kt/VAlexander S Goldfarb-Rumyantzev, Michael H Schwenk, Samuel Liu, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Kidney360|January 18, 2024
Carboplatin Dosing on the Basis of Renal Function: 30+ Years after CalvertMichael H Schwenk
Pharmacotherapy|December 25, 2009
Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney diseaseMichael H Schwenk
The New England Journal of Medicine|July 9, 2003
Eplerenone in patients with left ventricular dysfunctionDaniel A Blaustein, Michael H Schwenk
Advances in Chronic Kidney Disease|March 17, 2016
Drug Transporter Function--Implications in CKDMichael H Schwenk, Amy Barton Pai
Kidney International|June 1, 2012
Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?Jonathan Hogan, Michael H Schwenk, Jai Radhakrishnan
Advances in Chronic Kidney Disease|February 24, 2015
Aldosterone blockade in CKD: emphasis on pharmacologyMichael H Schwenk, Jamie S Hirsch, Andrew S Bomback
Nephron. Clinical Practice|February 28, 2004
Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron productsChaim Charytan, Michael H Schwenk, Mourhege M Al-Saloum, et al.
The American Journal of Cardiology|September 17, 2002
Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockadeDaniel A Blaustein, Krishnan Babu, Arpitha Reddy, et al.
Artificial Organs|June 5, 2003
Prediction of single-pool Kt/v based on clinical and hemodialysis variables using multilinear regression, tree-based modeling, and artificial neural networksAlexander Goldfarb-Rumyantzev, Michael H Schwenk, Samuel Liu, et al.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)|September 26, 2002
New empiric expressions to calculate single pool Kt/V and equilibriated Kt/VAlexander S Goldfarb-Rumyantzev, Michael H Schwenk, Samuel Liu, et al.
Pageof 2